Article
Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials.
The oncologist - 1 Jun 2016
Suh James H, Johnson Adrienne, Albacker Lee, Wang Kai, Chmielecki Juliann, Frampton Garrett, Gay Laurie, Elvin Julia A, Vergilio Jo-Anne, Ali Siraj, Miller Vincent A, Stephens Philip J, Ross Jeffrey S
Abstract excerpt
BACKGROUND: The National Comprehensive Cancer Network (NCCN) guidelines for patients with metastatic non-small cell lung cancer (NSCLC) recommend testing for EGFR, BRAF, ERBB2, and MET mutations; ALK, ROS1, and RET rearrangements; and MET amplification. We investigated the feasibility and utility of comprehensive genomic profiling (CGP), a hybrid capture-based next-generation sequencing (NGS) test, in clinical...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.